Corbus Pharmaceuticals reports Q1 EPS ($1.39), consensus ($1.07)

“During the first quarter of 2025, we continued to advance our pipeline by presenting encouraging CRB-701 Phase 1 solid tumor data from U.S. and U.K. sites at ASCO GU and initiating the CRB-913 Phase 1 study in obesity,” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. “We look forward to reporting clinical data from all three of our pipeline programs in the 2nd half of this year including: RP2D data from our Nectin-4 ADC, SAD/MAD data from our anti-obesity CB1 inverse agonist and the first ever dose escalation data in solid tumors for the anti- alphavbeta8 mAb. The data will be very informative in determining the next steps in our oncology and obesity programs and will form the basis of discussions with regulatory authorities and other relevant parties.”